Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO), has announced the successful validation of its microbial facilities—signifying that Scorpius’ microbial cleanrooms are now officially approved to manufacture current Good Manufacturing Practice (cGMP) microbial biologic drugs.
 
This achievement demonstrates Scorpius’ capability to meet the regulatory and client driven high standards required for contract manufacturing of microbial biologics.
 
In conjunction with the facility qualifications, Scorpius is also streamlining its operations by transitioning environmental monitoring responsibilities to internal teams, while it migrates from the previous reliance on third-party services. This shift is expected to allow for greater efficiency, further enhancing the Company’s ability to deliver quality biomanufacturing services.
 
“Scorpius has experienced strong interest in our microbial capabilities, and we continue to add additional opportunities to our pipeline for 2024 and 2025,” stated Jeff Wolf, CEO of Scorpius Holdings. “This validation confirms our commitment to high-quality, state-of-the-art microbial production. We are dedicated to leveraging our advanced capabilities to support our clients’ needs and contributing to the advancement of breakthrough therapies.”
 
“This validation is a testament to Scorpius’ rigorous quality standards and our dedication to supporting the development and manufacturing of microbial products. With this achievement, Scorpius is poised to further solidify its position as a leader in clinical scale microbial manufacturing, offering our clients unparalleled quality and service,” concluded Wolf.